Dornase alpha use in patients with cystic fibrosis
- PMID: 24473944
- PMCID: PMC4183042
- DOI: 10.1590/S0103-05822013000400001
Dornase alpha use in patients with cystic fibrosis
Conflict of interest statement
Conflito de interesse: nada a declarar
Comment on
-
A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study.Rev Paul Pediatr. 2013 Dec;31(4):420-30. doi: 10.1590/S0103-05822013000400002. Rev Paul Pediatr. 2013. PMID: 24473945 Free PMC article. Clinical Trial.
References
-
- Raskin S, Pereira-Ferrari L, Reis FC, Abreu F, Marostica P, Rozov T, et al. Incidence of cystic fibrosis in five different states of Brazil as determined by screening of p.F508del, mutation at the CFTR gene in newborns and patients. J Cyst Fibros. 2008;7:15–22. - PubMed
-
- Chernick WS, Barbero GJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics. 1959;24:739–745. - PubMed
-
- Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash M, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331:637–642. - PubMed
-
- Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J. 2011;37:806–812. - PubMed
-
- Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, et al. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Chest. 2005;128:2327–2335. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
